title: Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
abstract: Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.
authors.affiliation: BCLC Group, IDIBAPS, Liver Unit, Hospital Clínic Barcelona, Villarroel 170, 08036 Barcelona, Spain.
authors.forename: Augusto
authors.initials: A
authors.lastname: Villanueva
authors.forename: Josep M
authors.initials: JM
authors.lastname: Llovet
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D014227:Triazines; C509922:brivanib; D000409:Alanine